Investors were celebrating after hopeful news around a potential coronavirus vaccine. Spencerjakab explains why they should still be cautious. WSJWhatsNow
Even highly encouraging news about a possible vaccine doesn’t remove risks to hot biotech shares with high price tags
Understanding how the body clears the new coronavirus is becoming more important as the U.S. begins to reopen. WSJ’s Daniela Hernandez explains how the body fights infection and why feeling better doesn’t equal being virus-free. Photo illustration: Laura Kammermann
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stocks rebound as positive Moderna vaccine trial boosts optimism for economic recoveryStocks bounced back Monday on optimism the U.S. economy may start to recover from the coronavirus pandemic after drugmaker Moderna released promising early results for a vaccine.
Read more »
Stocks making the biggest moves midday: Moderna, Delta, Bank of America, Best Buy, Disney & moreModerna shares spike on 'positive data' from its coronavirus vaccine trial. Netflix shares slip as investors rotate out of 'stay-at-home' stocks.
Read more »
Coronavirus live updates: 'Positive' vaccine data lifts Moderna stock; Spain's GDP could fall more than 9.5%Covid-19 has now infected more than 4.7 million people around the world as of Monday, killing at least 315,496 people.
Read more »
Dow futures surge 600 points, adding to Monday gains as Moderna says it sees some success with coronavirus vaccineU.S. stock-index futures added to gains Monday morning, with the market for risk assets gathering additional momentum from a report of success in a vaccine...
Read more »
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.
Read more »